Oncology Briefings™: Targeting Treatment of Metastatic Melanoma with Oncolytic Viral Therapy

Release Date: March 24, 2021
Expiration Date: March 24, 2022

Activity Overview

This online activity is designed to provide a concise and focused overview on an important clinical topic. It includes current treatment options for metastatic melanoma, current intratumoral immunotherapy options, and recent safety and efficacy data supporting the use of intratumoral viral therapy. The engaging, multimedia format of this program includes audio commentary from an expert thought leader integrated with text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Amgen, Inc.

Target Audience

This educational program is directed toward medical oncologists and surgical oncologists who treat patients with melanoma. Fellows, nurses, nurse practitioners, physician assistants, and other health care professionals (HCPs) involved in the treatment of melanoma are also invited to participate in this activity.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe recent data from clinical trials evaluating oncolytic viral therapies for the treatment of advanced melanoma
• Explain distinguishing characteristics of emerging oncolytic viral agents currently undergoing evaluation in clinical trials for the treatment of patients with advanced melanoma
• Discuss the rationale of key synergistic strategies being explored for improving the efficacy of oncolytic viral therapy in patients with advanced melanoma
• Integrate best practices in monitoring and mitigating adverse events associated with oncolytic viral therapy based on safety data from clinical trials

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Omid Hamid, MD
Chief, Translational Research & Immuno-Oncology
Co-Director, Cutaneous Malignancies
The Angeles Clinic and Research Institute
Director of Experimental Therapeutics Cedars Sinai Medical Care Foundation
The Angeles Clinic and Research Institute
Los Angeles, CA

Disclosures: Grant/Research Support: (Contracted research for Institution) Arcus, Aduro, Akeso, Amgen, Bioatla, Bristol Myers Squibb, CytomX, Exelixis, Genentech, GSK, lmmunocore, ldera, Incyte, lovance, Merck, Moderna, Merck Serono, Nextcure, Novartis, Pfizer, Sanofi Regeneron, Seattle Genetics, Torgue, Zelluna. Consultant: Aduro, Akeso, Amgen, Beiqene, Bioatl, BMS, Genentech, GSK, lmmunocore, ldera, lncyte, Janssen, Merck, Nextcure, Novartis, Pfizer, Sanofi Regeneron, Seattle Genetics, Tempus, Zelluna. Speaker's Bureau: Bristol Myers Squibb, Novartis, Pfizer, Sanofi Regeneron.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.